Vaccine construction for human papilloma virus (HPV) type 16 and 18 Infection using in silico approach to combat cervical cancer

  • Muhammad Alsyifaa Dharmawan aBiomedical Engineering, Department of Electrical Engineering, Faculty of Engineering, Universitas Indonesia, Depok, Indonesia
  • Arif Nur Muhammad Ansori Doctoral Program in Veterinary Science, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia
  • Farida Aryani Dian Biotechnology, Department of Biochemistry and Biotechnology, Faculty of Agronomy, Horticulture, and Bioengineering, Poznan University of Life Sciences, Poznan, Poland
  • Rasyadan Taufiq Probojati Division of Molecular Biology and Genetics, Generasi Biologi Indonesia Foundation, Gresik, East Java
  • Muhammad Badrut Tamam Department of Biology, Faculty of Sciences and Technology, Universitas Muhammadiyah Lamongan, Lamongan, Indonesia
  • Viol Dhea Kharisma Biology, Biology Department, Faculty of Mathematic and Natural Sciences, Universitas Brawijaya, Malang, Indonesia
Keywords: Epitope-based peptide vaccine; Human papillomavirus; Immunoinformatics.

Abstract

Human papillomavirus (HPV) is a virus that causes infection on the surface of the skin and has the potential to cause cervical cancer. This viral infection is characterized by the growth of warts on the skin in various areas of the body, such as the arms, legs, mouth, and genital area. Because the virus can endanger health, it is necessary to design an HPV vaccine to overcome this problem. In this study, we performed a study characterization of HPV types 16 and 18 sequences to obtain immunogenic epitopes retrieved from the National Center for Biotechnology Information (NCBI) web server. Then, epitope prediction was performed using the immune epitope database (IEDB) web server and selected to get the best vaccine candidate for HPV types 16 and 18. We recommend 16P1 as an epitope-based peptide vaccine candidate for HPV type 16 and 18P4 for type 18. Both vaccine candidates are antigenic, non-allergenic, and non-toxic. The 16P1 and 18P4 have the lowest global energy values ​​among the other candidates. However, further research is needed to be able to develop the best vaccine (in vitro and in vivo experiments).

 

Downloads

Download data is not yet available.

References

1. Dadar, M., Chakraborty, S., Dhama, K., Prasad, M., Khandia, R., Hassan, S., Munjal, A., Tiwari, R., Karthik, K., Kumar, D., Iqbal, H., & Chaicumpa, W. Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus. Frontiers in immunology. 2018; 9: 2478. https://doi.org/10.3389/fimmu.2018.02478I.
2. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010; 401, 70–79. doi: 10.1016/j.virol.2010.02.002
3. Burk, R. D., Harari, A., & Chen, Z. Human papillomavirus genome variants. Virology. 2013; 445(1-2), 232–243. https://doi.org/10.1016/j.virol.2013.07.018.
4. Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 2015; 6, 281–290.
5. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA, 2012. The biology and life-cycle of human papillomaviruses. Vaccine. 2012, 30 (5), F55–70.
6. Bonanni P, Bechini A, Donato R, et al. Human papilloma virus vaccination: impact and recommendations across the world. Ther Adv Vaccines. 2014, 3:3–12. 10.1177/2051013614557476
7. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 2012. Biological agents, vol 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 100:1–441.
8. Tomaić V. 2016. Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites. Cancers. 8:95. doi:10.3390/cancers8100095.
9. Greenwood B The contribution of vaccination to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014;369(1645):20130433.
10. Chua, H., Feng, S., Lewnard, et al (2020). The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology. Epidemiology (Cambridge, Mass.), 31(1), 43–64. https://doi.org/10.1097/EDE.0000000000001116
11. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. Am J Epidemiol. 2016;184(5):345–53.
12. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 2003;31:3381-3385. https://doi. org/10.1093/nar/gkg520
13. Ansori ANM, Kharisma VD. Characterization of Newcastle disease virus in Southeast Asia and East Asia: Fusion protein gene. Eksakta. 2020;1:20-28. https://doi.org/10.20885/EKSAKTA.vol1.iss1.art3
14. Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and methods for T- and B-cell epitope prediction. J Immunol Res. 2017;2017:2680160. https://doi.org/10.1155/2017/2680160
15. Hilyatuz Z, Ma'rup A, Tambunan USF, Parikesit AA. Immunoinformatics approach in designing epitope based vaccine against meningitis-inducing bacteria (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae Type B). Drug Target Insights. 2016;10:19-29. https://doi.org/10.4137/DTI. S38458
16. Kozakov D, Hall DR, Xia B, et al. The ClusPro web server for protein-protein docking. Nat Prot. 2017;12:255- 278. https://doi.org/10.1038/nprot.2016.169
17. Himmah K, Fitriyah, Ardiyati T, Deocaris C, Widodo N. Polytope prediction for dengue vaccine candidate based on conserved envelope glycoprotein of four serotypes of Dengue virus and its antigenicity. J Pure App Chem Res. 2016;5(2):101-107. https://doi. org/10.21776/ub.jpacr.2016.005.02.290
18. Fu Y, Zhao J, Chen Z. Insights into the molecular mechanisms of protein-ligand interactions by molecular docking and molecular dynamics simulation: A case of oligopeptide binding protein. Comput Math Methods Med. 2018;2018:350-2514. https://doi. org/10.1155/2018/3502514
Published
2021-11-03
How to Cite
Dharmawan, M. A., Ansori, A. N. M., Dian, F. A., Probojati, R. T., Tamam, M. B., & Kharisma, V. D. (2021). Vaccine construction for human papilloma virus (HPV) type 16 and 18 Infection using in silico approach to combat cervical cancer. Genbinesia Journal of Biology, 1(1), 13-22. https://doi.org/10.55655/genbinesia.v1i1.3

Most read articles by the same author(s)